Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Ebola Vaccines: FDA Advisory Committee Convenes As Outbreak Recedes

This article was originally published in The Pink Sheet Daily

Executive Summary

Challenge of testing vaccines when infections seem to be coming under control is among potential issues for May 12 meeting.

You may also be interested in...



Ebola Drugs Take Center Stage In Review Voucher Bill, But Real Value May Be Harmonization

Along with adding Ebola to list of disease treatments eligible for tropical disease priority review voucher, bill moving through Congress would cut notification time required before redemption.

Ebola Treatments Could Be Orphan Candidates – But Vaccines, Probably Not

FDA expects few people would get the disease in the U.S., but many could receive a vaccine.

As US FDA’s Principal Deputy Commissioner, Woodcock Focusing On Food Issues

Commissioner Robert Califf wants Janet Woodcock to improve food operations and processes, but lawmakers question whether she is the best overseer for the area.

Topics

Related Companies

UsernamePublicRestriction

Register

PS078270

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel